Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma Journal Article


Authors: Judge, S. J.; Manin, E.; Chou, J.; Torphy, R. J.; McIntyre, C. A.; Balachandran, V. P.; D'Angelica, M. I.; Drebin, J. A.; Gönen, M.; Jarnagin, W. R.; Kingham, T. P.; O'Reilly, E. M.; Park, W.; Wei, A. C.; Zervoudakis, A.; Soares, K. C.
Article Title: Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma
Abstract: <p>Background: The influence of obesity and sex on outcomes in pancreatic adenocarcinoma (PDAC) remains unclear. The association between obesity (body mass index [BMI], >= 30) and biologic sex (male or female) for outcomes in patients with PDAC undergoing a surgery-first approach was investigated. Methods: A prospectively maintained pancreatic cancer database at the Memorial Sloan Kettering Cancer Center was queried to identify all patients undergoing surgery with a pathologic diagnosis of PDAC. Clinicodemographic variables, outcomes, and tumor mutational analyses for all available patients were collected. Cumulative incidence of first recurrence involving the liver was estimated via a cumulative incidence function. Multivariable Cox regression was used to investigate the association between BMI and sex for overall survival. Results: From 2012 to 2022, 939 patients were identified who underwent surgery with a final pathologic diagnosis of PDAC. Median age was 70 years, 52% were male, and 24% were obese (BMI, >= 30). When dichotomized by sex and obesity status (BMI, <30 or >= 30), females with obesity had the lowest cumulative incidence of liver recurrence at 12 and 24 months postsurgery compared to all other groups (13% [95% CI, 7.2%-20%] and 15% [8.7%-23%], respectively). Females with obesity had the longest median overall survival at 37 months. Conclusions: After curative surgery for pancreatic cancer, females with obesity have a significantly lower rate of liver recurrence and the longest median overall survival. This does not appear to be related to surgical quality, receipt of adjuvant therapy, or tumor mutational profile. Investigation into host immune, metabolic, and hormonal parameters is paramount to understanding these differences.</p>
Keywords: chemotherapy; obesity; age; risk; pancreatic cancer; outcomes; impact; body-mass index; sex differences; cancer; liver recurrence
Journal Title: Cancer
Volume: 131
Issue: 18
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2025-09-15
Start Page: e70088
Language: English
ACCESSION: WOS:001575798000009
DOI: 10.1002/cncr.70088
PROVIDER: wos
PMCID: PMC12421944
PUBMED: 40928210
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK authors are Sean J. Judge and Kevin C. Soares -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joanne Fu-Lou Chou
    342 Chou
  2. Mithat Gonen
    1039 Gonen
  3. William R Jarnagin
    917 Jarnagin
  4. T Peter Kingham
    627 Kingham
  5. Eileen O'Reilly
    801 O'Reilly
  6. Jeffrey Adam Drebin
    172 Drebin
  7. Wungki Park
    102 Park
  8. Alice Chia-Chi Wei
    213 Wei
  9. Kevin Cerqueira Soares
    147 Soares
  10. Sean James O'Day Judge
    13 Judge
  11. Emily Manin
    2 Manin
  12. Robert J Torphy
    6 Torphy